We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.54B
1-Year Est. Return 86.39%
This Fund
S&P 500
This Quarter Est. Return
+20.01%
1 Year Est. Return
+86.39%
3 Year Est. Return
-13.28%
5 Year Est. Return
-50.7%
10 Year Est. Return
+414.55%
AUM
$268M
AUM Growth
+$32.7M
Cap. Flow
-$18
Cap. Flow %
-0%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
MCRB icon
Seres Therapeutics
MCRB
+$18

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$57.4B
$128M 47.6%
4,632,149
– –
SANA icon
2
Sana Biotechnology
SANA
$946M
$68.3M 25.42%
25,001,856
– –
FHTX icon
3
Foghorn Therapeutics
FHTX
$245M
$59.6M 22.19%
12,674,120
– –
MCRB icon
4
Seres Therapeutics
MCRB
$46.2M
$12.8M 4.78%
1,155,850
-2
-0% -$18

Similar funds

SPC
Stony Point Capital New York $1.54B AUM 54.05% 1-Year Est. Return
AWC
Abundance Wealth Counselors State College, Pennsylvania $1.54B AUM 31.07% 1-Year Est. Return
SMC
Smith, Moore & Co Clayton, Missouri $1.54B AUM 24.82% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return
BOF
Bank of Finland Helsinki, Finland $1.54B AUM 15.84% 1-Year Est. Return
KCM
Kanawha Capital Management Richmond, Virginia $1.54B AUM 21.3% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.54B AUM 27.61% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return

Flagship Pioneering's Q2 2025 Portfolio in Review

As of Q2 2025, Flagship Pioneering held 4 positions worth $268M, up 14% from $236M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 0%. Flagship Pioneering opened no new positions and made no exits, leaving the 4-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Flagship Pioneering's biggest Q2 2025 reduction was Seres Therapeutics, cutting an estimated $18.
  • Flagship Pioneering's ten largest holdings make up 100% of its $268M portfolio in Q2 2025.
  • Flagship Pioneering opened 0 new positions and closed 0 in Q2 2025.
  • Flagship Pioneering's portfolio value rose 14% quarter-over-quarter to $268M.

Based on Flagship Pioneering's 13F filing for Q2 2025, filed 14 Aug 2025.